Pharma execs doubt AI can cure most diseases in ten years; US FDA still hasn’t approved any AI‑designed biotech drugs
| Source: Techmeme | Original article
Pharma executives doubt AI’s promise to cure most diseases within ten years, as the FDA has not yet approved any AI‑designed biotech drug.
Pharmaceutical executives are pushing back against the hype that artificial intelligence will cure most diseases within the next ten years, according to a Wall Street Journal report by Xavier Martinez. The article notes that, despite rapid advances in generative models and data‑driven drug discovery, the U.S. Food and Drug Administration has not yet granted clearance to any biotech product that was designed primarily by AI.
The skepticism reflects a gap between academic optimism and regulatory reality. While AI tools can accelerate target identification and molecular design, the FDA’s approval process still demands extensive pre‑clinical testing, clinical trials and evidence of safety and efficacy—steps that cannot be shortcut by algorithms alone. Industry leaders warn that over‑promising AI’s curative potential could mislead investors and erode public trust, especially as the sector seeks to justify soaring R&D budgets.
The lack of FDA‑cleared AI‑designed drugs matters for several reasons. First, it underscores that AI is currently a supplement rather than a substitute for traditional pharmaceutical pipelines. Second, it signals to venture capital and biotech firms that commercial returns will still hinge on navigating the same regulatory hurdles as conventional candidates. Finally, it highlights the need for clearer guidance on how AI‑generated data should be integrated into submission dossiers.
Going forward, observers will watch for any pilot programs or collaborative frameworks between AI developers and regulators that could pave a path to formal approval. The FDA’s upcoming guidance on software‑as‑a‑medical‑device and its recent interest in digital health tools may hint at how AI‑driven drug design will be evaluated. Until an AI‑designed therapy clears the agency’s bar, the promise of a decade‑long disease‑curing revolution remains speculative.
Sources
Back to AIPULSEN